Poly(ADP-ribose) Polymerase Inhibitors: all 983 studies that test it

Page 7 of 10. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.

• Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract CancerWithdrawnNCT04796454Phase 2
• Functional Analysis of BRCAnessTerminatedNCT04780945Phase 2
• Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and DostarlimabTerminatedNCT04779151Phase 2
• Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid TumorsStatus unknownNCT04764084Phase 1
• Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast CancerWithdrawnNCT04756765Phase 2
• Talazoparib Maintenance Therapy in Triple-negative Breast CancerStatus unknownNCT04755868Phase 2
• Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Active, not recruitingNCT04753879Phase 2
• Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)Active, not recruitingNCT04748042Phase 2
• Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRdCompletedNCT04740190Phase 2
• Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - CYMEVALIII STEP1CompletedNCT04732260Not applicable
• Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO TrialActive, not recruitingNCT04728230Phase 1/2
• Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric CancerActive, not recruitingNCT04725994Phase 1/2
• A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian CancerCompletedNCT04718740Phase 1
• Niraparib Combined With Radiotherapy in rGBMStatus unknownNCT04715620Phase 2
• Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain MetastasesActive, not recruitingNCT04711824Phase 1/2
• Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerCompletedNCT04703920Phase 1
• Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasActive, not recruitingNCT04701307Phase 2
• Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver FunctionCompletedNCT04694365Phase 1
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT04691804Phase 3
• Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum RetreatmentStatus unknownNCT04679064Phase 3
• Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04673448Phase 1
• EP0057 in Combination With Olaparib in Advanced Ovarian CancerCompletedNCT04669002Phase 2
• A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based TherapyActive, not recruitingNCT04666740Phase 2
• A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）Status unknownNCT04659785Phase 1/2
• Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT04643379Phase 2
• Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical CancerStatus unknownNCT04641728Phase 2
• Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) MutationStatus unknownNCT04633902Phase 2
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active, not recruitingNCT04624204Phase 3
• Study of Pamiparib in Newly Diagnosed and rGBMCompletedNCT04614909Early Phase 1
• Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell CancerWithdrawnNCT04603365Phase 2
• Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04592237Phase 2
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
• IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male VolunteersCompletedNCT04584515Phase 1
• Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical CystectomyTerminatedNCT04579133Phase 2
• A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate CancerActive, not recruitingNCT04577833Phase 1
• Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerStatus unknownNCT04566952Phase 2
• Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian CancerStatus unknownNCT04556539Phase 2
• A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer PatientsStatus unknownNCT04556292Phase 2
• Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian CancerStatus unknownNCT04556071Phase 2
• A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent GlioblastomaStatus unknownNCT04552977Phase 2
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsActive, not recruitingNCT04550494Phase 2
• Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell CarcinomaCompletedNCT04535687Phase 2
• Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult SubjectsCompletedNCT04521192Phase 1
• A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer PatientsCompletedNCT04517357Phase 2
• Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian CancerActive, not recruitingNCT04507841Phase 2
• First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid TumorsCompletedNCT04505839Phase 1
• Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian CancerActive, not recruitingNCT04502602Phase 1
• A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical CancerActive, not recruitingNCT04487587Phase 2
• Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOtheliomaStatus unknownNCT04462809Phase 2
• IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung CancerCompletedNCT04434482Phase 1/2
• A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic CancerStatus unknownNCT04425876Phase 1
• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibActive, not recruitingNCT04421963Phase 3
• Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian CancerCompletedNCT04417192Phase 2
• Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine CancerActive, not recruitingNCT04394858Phase 2
• A Study of Niraparib in Patients With Relapsed Ovarian CancerCompletedNCT04392102Phase 2
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Active, not recruitingNCT04380636Phase 3
• Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04376073Phase 2
• 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive TumoursCompletedNCT04375267Phase 1
• Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
• BA Study of IMP4297 (20mg vs 10mg) in Healthy Male SubjectsCompletedNCT04351165Phase 1
• Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.Active, not recruitingNCT04348045Phase 2
• Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese SubjectsStatus unknownNCT04341077Phase 1
• A Study of NOV140201 (JPI-547) in Subject With Advanced Solid TumorsCompletedNCT04335604Phase 1
• Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive BiomarkerActive, not recruitingNCT04334941Phase 2
• A Trial of SHR3162 in Healthy Caucasian VolunteersCompletedNCT04333134Phase 1
• Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)CompletedNCT04332744Phase 2
• A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyTerminatedNCT04300114Phase 3
• DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract CancerActive, not recruitingNCT04298021Phase 2
• Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant SettingCompletedNCT04284852Phase 2
• Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsTerminatedNCT04276376Phase 2
• ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian CancerTerminatedNCT04267939Phase 1
• NUVOLA TRIAL Open-label Multicentre StudyStatus unknownNCT04261465Phase 2
• A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT04253262Phase 1/2
• Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)CompletedNCT04240106Phase 2
• A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.WithdrawnNCT04239014Phase 2
• Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid TumoursCompletedNCT04236414Phase 1
• Phase I Study of SYD985 With Niraparib in Patients With Solid TumorsCompletedNCT04235101Phase 1
• A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based ChemotherapyStatus unknownNCT04229615Phase 3
• A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic CancerCompletedNCT04228601Phase 1/2
• Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer PatientsCompletedNCT04227522Phase 3
• Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian CancerStatus unknownNCT04217798Phase 2
• Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT04207190Phase 1
• Effect of Fluconazole on PK of Fluzoparib in Healthy Male SubjectsCompletedNCT04193319Phase 1
• A MolEcularly Guided Anti-Cancer Drug Off-Label TrialActive, not recruitingNCT04185831Phase 2
• Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid TumorsTerminatedNCT04182516Phase 1
• Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)CompletedNCT04174716Phase 1/2
• Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib TreatmentActive, not recruitingNCT04169841Phase 2
• Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedNCT04164199Phase 3
• A Study of Various Treatments in Serous or p53 Abnormal Endometrial CancerTerminatedNCT04159155Phase 2/3
• Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian CancerWithdrawnNCT04149145Phase 1
• Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast CancerCompletedNCT04134884Phase 1
• Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)CompletedNCT04123366Phase 2
• Effect of Omeprazole on PK of Fluzoparib in Healthy Male SubjectsCompletedNCT04108676Phase 1
• A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPCStatus unknownNCT04108247Phase 1
• A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPCTerminatedNCT04102124Phase 2
• Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational StudyStatus unknownNCT04091204Phase 2
• Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian CancerCompletedNCT04089189Phase 2
• Trial of Maintenance With Niraparib- Uterine Serous CarcinomaCompletedNCT04080284Phase 2
• Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix CancerActive, not recruitingNCT04068753Phase 2
• ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingNCT04065269Phase 2

← Poly(ADP-ribose) Polymerase Inhibitors overview